1 Department of Medical Oncology, Ege University Medical Faculty, Izmir, Türkiye 2 Department of Pathology, Ege University Medical Faculty, Izmir, Türkiye Introduction: Adjuvant anti–PD-1 therapy has ...

Adjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved invasive disease-free survival compared with trastuzumab emtansine (T-DM1; Kadcyla) in high-risk HER2-positive early breast ...

The US is seeking to expand its strategic relationship with Pakistan but those ties don’t come at the expense of Washington’s relations with India, Secretary of State Marco Rubio said. Just like India ...

T-Mobile US Inc. posted better-than-expected subscriber growth in the third quarter, but the shares fell as investors focused on the increasing competition for new customers among the top wireless ...

SCOTTSDALE, AZ — While most of the research on the role of GLP-1 receptor agonists (RAs) in thyroid cancer has focused on their potential to trigger such cancer, new research found that among patients ...

The partnership will give Goldman access to T. Rowe's massive retirement-focused client base, which is seen as a stable income stream and a big opportunity. "Goldman did not buy a friend, it bought a ...

Section 1. Determinations. The agencies and agency subdivisions set forth in section 2 of this order are hereby determined to have as a primary function intelligence, counterintelligence, ...

Millions of AT&T customers can now file claims in a $177 million legal settlement related to two data breaches, which could provide up to $7,500 in compensation per person. Multiple lawsuits were ...

In an early trial, a one-size-fits-all vaccine showed promise in preventing hard-to-treat pancreatic cancers from coming back. Pancreatic cancer is of particular concern. The five-year survival rate ...

The EU risks losing €1.2 trillion ($1.3trn) in GDP if it fails to address anti-competitive practices in the region’s cloud market, a new report claims. Commissioned by the cloud lobbying group, the ...

AbbVie is making a full strength play for the in vivo CAR-T market, snapping up Capstan Therapeutics for $2.1 billion to add an early-phase autoimmune drug candidate to its pipeline. Capstan is part ...